SCHEMBL15664000

SCHEMBL15664000

CCOC(=O)c1c(C)nc2c(OCc3c(F)cccc3F)cc(F)cn12

nearest known ligand 0.49

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
GUCY1B2 O75343 17/20 0.49
GUCY1A2 P33402 17/20 0.49
GUCY1A1 Q02108 17/20 0.49
GUCY1B1 Q02153 17/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
HCRTR1 O43613 1/20 0.46
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15663607 0.92 GUCY1B2 (0.49) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15664140 0.90 GUCY1B2 (0.48) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15663883 0.90 GUCY1B2 (0.48) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15812517 0.89 GUCY1B2 (0.47) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15812774 0.89 GUCY1B2 (0.51) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15664222 0.88 GUCY1B2 (0.52) GUCY1B2GUCY1A2GUCY1A1GUCY1B1
SCHEMBL15671546 0.88 GUCY1B2 (0.47) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15812312 0.88 GUCY1B2 (0.49) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15665236 0.87 GUCY1B2 (0.46) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2
SCHEMBL15812153 0.87 GUCY1B2 (0.46) GUCY1B2GUCY1A2GUCY1A1GUCY1B1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 US disclosed
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-05-26 US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 US disclosed
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-08-15 US disclosed
US-20180319794-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-08 US disclosed
US-10052312-B2 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-08-21 US disclosed
EP-3272749-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE Bayer Pharma Aktiengesellschaft (DE) 2018-01-24 EP disclosed
US-9771360-B2 Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-26 US disclosed
US-9771360-B2 Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-26 US disclosed
US-20170217954-A1 CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-08-03 US disclosed
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-06-26 US disclosed
US-20140128372-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128372-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128372-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128386-A1 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128424-A1 Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128424-A1 Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128424-A1 Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128386-A1 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed
US-20140128386-A1 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217954-A1 CYANO-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PCCA GUCY1B2 454/4885GUCY1A2 264/4885GUCY1A1 477/4885
US-20140128386-A1 Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAH GUCY1B2 793/4885GUCY1A2 719/4885GUCY1A1 1052/4885
US-20140128372-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS GUCY1B2 669/4885GUCY1A2 550/4885GUCY1A1 925/4885
US-20140179672-A1 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS GUCY1B2 669/4885GUCY1A2 550/4885GUCY1A1 925/4885
US-10052312-B2 Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use AADAC, TNNI3, PAICS GUCY1B2 669/4885GUCY1A2 550/4885GUCY1A1 925/4885
US-20140128424-A1 Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use TNNI3, AADAC, TNNT2 GUCY1B2 866/4885GUCY1A2 684/4885GUCY1A1 1084/4885
US-20190248783-A9 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS GUCY1B2 669/4885GUCY1A2 550/4885GUCY1A1 925/4885
US-10662185-B2 Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use AADAC, TNNI3, TNNT2 GUCY1B2 410/4885GUCY1A2 174/4885GUCY1A1 352/4885
US-20180319794-A1 AMINO-SUBSTITUTED IMIDAZO[1,2-A] PYRIDINECARBOXAMIDES AND THEIR USE AADAC, TNNI3, PAICS GUCY1B2 669/4885GUCY1A2 550/4885GUCY1A1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.